Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12880682 | 0.85 | IRAK4 (0.35) | IRAK4 | |
| SCHEMBL12880658 | 0.85 | IRAK4 (0.35) | IRAK4 | |
| SCHEMBL22107550 | 0.81 | HOGA1 (0.32) | — | |
| SCHEMBL10110585 | 0.79 | — | — | |
| SCHEMBL14561267 | 0.79 | — | — | |
| SCHEMBL16889285 | 0.79 | — | — | |
| SCHEMBL4458205 | 0.79 | — | — | |
| SCHEMBL16889289 | 0.79 | — | — | |
| SCHEMBL9975267 | 0.77 | — | — | |
| SCHEMBL6980323 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994346-B2 | such as methyl 2-({(4S,5R)-5-[(1E,3E,7E)-(S)-10-(4-fluorophenoxy)-9-hydroxydeca-1,3,7-trien-5-yn-1-yl]-2,2-dimethyl-1,3-dioxolan-4-yl}methoxy)acetate, useful in treating inflammatory and autoimmune disorders in humans | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7928255-B2 | Intermediates for the preparation of lipoxin A4 analogs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-19 | — | — | US | disclosed |
| US-20080119439-A1 | Treatment and prevention of intestinal fibrosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2008-05-22 | — | — | US | disclosed |
| US-20070129578-A1 | Method for the production of 2,2'-dihydroxybiphenyls | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | US | disclosed |
| US-7223798-B2 | Lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-10 | — | — | US | disclosed |
| EP-1682473-A1 | METHOD FOR THE PRODUCTION OF 2,2'-DIHYDROXYBIPHENYLS | BASF Aktiengesellschaft (DE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005042454-A1 | METHOD FOR THE PRODUCTION OF 2,2'-DIHYDROXYBIPHENYLS | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | WO | disclosed |
| US-4058462-A | System for sustained release of phenolic material from porous granules of insoluble polymeric phenolic complexes | GAF CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4009039-A | Heat developable light-sensitive oxazoline containing element | FUJI PHOTO FILM CO., LTD. (JA) | 1977-02-22 | — | — | US | disclosed |
| US-3985540-A | Metal complexes of hydroxyquinoline and polymeric porous granules | GAF CORPORATION (US) | 1976-10-12 | — | — | US | disclosed |
| US-3954682-A | GRANULES OR BEADS | GAF CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129578-A1 | Method for the production of 2,2'-dihydroxybiphenyls | HAO2, DAO, DDO | IRAK4 3355/4885 |
| US-20080119439-A1 | Treatment and prevention of intestinal fibrosis | LTA4H, FABP2, LTB4R | IRAK4 1315/4885 |
| US-20070105949-A1 | Intermediates for the preparation of lipoxin A4 analogs | LTB4R, LTB4R2, LTC4S | IRAK4 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.